Furthermore, we analyzed the clinical characteristics of these 92 PAAD patients (Supplementary Table 11) and found that those with high expression levels of SP100 had significantly shorter overall survival time (p = 0.006) (Figure 6E). The gene discussed is SP100; the disease is pancreatic adenocarcinoma.